Locust Walk analyzed the evolving landscape of China’s biotech out-licensing market and its impact on global dealmaking.
The Deal Makers of Japan series aims to bridge the gap and offer insight to a global biopharma audience to the Japanese pharma industry.
While these key pillars are not exhaustive and approaches may overlap between multiple, these areas have seen a great deal of innovation and attention from strategics and investors as a result.
Locust Walk has conducted an extensive study of mergers and acquisitions in biopharma completed in the past three years and uncovered an interesting trend leaders need to understand
Induced pluripotent stem cell (iPSC) research has encapsulated a global market of scientists, clinicians, and investors and has quickly become the foundation for new regenerative medicines.
The Covid-19 pandemic was the biggest biopharma news of 2020. It may be hard to remember now, but in March of last year, biotech indices had quickly nose-dived, along with the broader market, as the reality of the pandemic became apparent. The prevailing financial sentiment was doom and gloom.
Following up on our recent white paper, Biopharma’s COVID Capital Comeback, here is a look at the greatest risk facing public biopharma companies — single asset failures — and what they can do during this time of robust capital.
Heading into 2020, biopharma looked like it would be typecast in its typical election year role: the big business scapegoat for everything that’s wrong in health care. There had been the usual big Phase 3 trial failures.
COVID-19 or SARS Cov-2 to be precise, has changed the world in many regards. From the way we work, to the way we do business as well as to even what used to be the simplest thing – chatting over coffee. Now everything,
We are pleased to present the second series of the Deal Makers of Japan – Exclusive Interviews with Japan’s best dealmakers.